Dear Editors,
The ability of lasers to selectively destroy the melanin pigment responsible for solar/senile lentigines (SL) (age spots) without damaging the surrounding tissue makes laser therapy a preferred option for treating SL. 1 However, laser therapies typically utilize a high energy output to achieve thermal ablation of their selective targets-and therefore can be associated with a period of recovery, healing, and down time, depending on the modality. The Kleresca® biophotonic platform, which generates fluorescent light energy (FLE), is a non-invasive form of photobiomodulation with multiple applications. 2 FLE has clinical efficacy in treating inflammatory skin conditions such as acne vulgaris and rosacea, [3] [4] [5] [6] in addition to its healing and normalizing properties, rejuvenating the skin. 7 It has previously been combined with other invasive treatment techniques, for example, following picosecond laser treatment of SL, where it enhanced the overall appearance of the skin. Here, we present a 67-year-old woman with histologically confirmed SL ( Figure 1A Figure 1B) , and 3 weeks after the QS-ruby laser treatment ( Figure 1C ). Pictures were analyzed using ImageJ (NIH), the percentage area of pigmentation was measured ( Figure 1D) , and from this, the percentage change in pigmentation between treatments was calculated ( Table 1) .
Following the Kleresca ® treatment, there was an increase in the % area of pigmentation ( Figure 1B ; Table 1 ) compared with the baseline (before any treatment; Figure 1A ; Table 1 ). Following the subsequent QS-ruby laser treatment, the pigmentation decreased by 232%, ( Figure 1C ; Table 1 ).
By increasing the % area of pigmentation, the Kleresca ® treatment highlighted the SL spots to be targeted by the QS-ruby laser.
The complete mechanism for the emergence or darkening of underlying pigmented areas following the Kleresca® treatment has not been fully elucidated. However, since the pigment can become visible during a treatment session of only 9 minutes, it is clear that this is an immediate and transient pigmentation response acting on melanin already present in the skin, as opposed to inducing new melanin synthesis. Further, it differs from damage associated UV-induced hyperpigmentation.
Only one single session of the laser treatment was required to ablate the visible SL lesions. Hence, the treatment essentially prepared the skin by activating the skin cells and intensified the key areas to be targeted with the QS-ruby laser as well as enhancing its efficacy.
Since laser fluence, power and pulse duration are key determinants of the efficacy of laser treatment for SL, 1 the use of 
